Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Acquires 648,455 Shares of Company Stock

Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) major shareholder L1 Capital Pty Ltd purchased 648,455 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were bought at an average cost of $7.51 per share, with a total value of $4,869,897.05. Following the purchase, the insider directly owned 12,778,380 shares of the company’s stock, valued at approximately $95,965,633.80. This represents a 5.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

  • On Friday, October 2nd, L1 Capital Pty Ltd acquired 236,354 shares of Anteris Technologies Global stock. The stock was purchased at an average cost of $7.78 per share, for a total transaction of $1,838,834.12.
  • On Thursday, October 1st, L1 Capital Pty Ltd acquired 322,940 shares of Anteris Technologies Global stock. The shares were purchased at an average price of $7.60 per share, for a total transaction of $2,454,344.00.
  • On Wednesday, September 30th, L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock. The shares were purchased at an average cost of $7.72 per share, with a total value of $573,487.92.
  • On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.83, for a total value of $68,874.00.
  • On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.30, for a total value of $3,495,079.50.
  • On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total value of $2,291,780.40.
  • On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total value of $1,415,240.10.
  • On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
  • On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
  • On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $3,853,113.30.

Anteris Technologies Global Price Performance

Shares of Anteris Technologies Global stock opened at $7.05 on Wednesday. Anteris Technologies Global Corp. has a 1 year low of $3.30 and a 1 year high of $11.06. The firm’s 50-day moving average is $8.46 and its two-hundred day moving average is $8.01. The stock has a market cap of $687.08 million, a price-to-earnings ratio of -3.62 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $1.01 million for the quarter, compared to analysts’ expectations of $1.50 million. During the same period last year, the business posted ($0.58) EPS. On average, equities analysts expect that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current year.

Analysts Set New Price Targets

AVR has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price target on shares of Anteris Technologies Global in a report on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Finally, Barclays initiated coverage on shares of Anteris Technologies Global in a research note on Tuesday. They issued a “positive” rating and a $10.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Anteris Technologies Global presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Check Out Our Latest Research Report on AVR

Hedge Funds Weigh In On Anteris Technologies Global

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC acquired a new position in Anteris Technologies Global during the 2nd quarter valued at approximately $33,325,850. One68 Global Capital LLC purchased a new position in shares of Anteris Technologies Global in the second quarter worth $128,000. Bank of America Corp DE acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $1,907,000. AWM Investment Company Inc. acquired a new stake in shares of Anteris Technologies Global during the second quarter worth $1,133,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the second quarter valued at $30,979,000.

Anteris Technologies Global Company Profile

(Get Free Report)

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.

Recommended Stories

Insider Buying and Selling by Quarter for Anteris Technologies Global (NASDAQ:AVR)

Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.